Leishmaniasis

Disclaimer: > [!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols.

1. Clinical Overview

Leishmaniasis is a vector-borne protozoal infection caused by obligate intracellular parasites of the genus Leishmania and transmitted through the bite of infected female Phlebotomine sandflies. It represents one of the most important neglected tropical diseases (NTDs), affecting the world's poorest populations with an estimated 1 million new cases annually and 12 million people currently infected globally. [1,2]

The disease manifests in three distinct clinical forms depending on the infecting Leishmania species and host immune response:

The Three Clinical Forms

1. Cutaneous Leishmaniasis (CL): The most common form (95% of cases), characterized by localized skin ulcers that may heal spontaneously or require treatment. Causes significant morbidity through disfiguring scars and psychosocial stigma. [3,4]

2. Mucocutaneous Leishmaniasis (MCL): A severe metastatic form affecting nasopharyngeal mucosa, leading to progressive destruction of nasal septum, palate, and facial structures. Primarily caused by Leishmania braziliensis in the Americas. Does not heal spontaneously and requires aggressive systemic therapy. [5]

3. Visceral Leishmaniasis (VL) / Kala-Azar: The most severe form with systemic invasion of the reticuloendothelial system (liver, spleen, bone marrow). Presents with prolonged fever, massive splenomegaly, pancytopenia, and progressive cachexia. Fatal in > 95% of untreated cases within 2 years. [6,7]

Global Public Health Impact

• Geographic Distribution: Endemic in 98 countries across tropical and subtropical regions
• Annual Incidence: 700,000-1,000,000 new cases (CL); 50,000-90,000 new cases (VL)
• Mortality: 20,000-30,000 deaths annually, primarily from VL
• Disability-Adjusted Life Years (DALYs): 2.1 million DALYs lost per year
• Risk Groups: Poverty, malnutrition, population displacement, immunosuppression (HIV co-infection)
• Climate Sensitivity: Expanding geographic range due to climate change and deforestation [1,2]

---

2. Visual Summary Panel

Image Integration Plan

[!NOTE] Image Generation Status: High-priority diagrams illustrating the Amastigote/Promastigote transformation cycle and management algorithms are queued for generation.

Pathognomonic Clinical Signs

Cutaneous Leishmaniasis

• Volcano Sign: Painless ulcer with raised, indurated, "heaped-up" edge and central necrotic crater
• Satellite Lesions: Multiple papules surrounding the primary lesion due to local lymphatic spread
• Sporotrichoid Pattern: Linear nodules along lymphatic drainage (rare, mimics sporotrichosis)
• Baghdad Boil: Term used for Old World CL, particularly in Middle East conflicts

Visceral Leishmaniasis

• Massive Splenomegaly: One of the largest spleens in medicine—can extend across midline into right iliac fossa
• Kala-Azar (Hindi): "Black fever"—skin hyperpigmentation, particularly on hands, feet, abdomen in dark-skinned individuals
• Double Daily Fever Spikes: Irregular pyrexia pattern with characteristically two peaks per day
• Hepatosplenomegaly Ratio: Spleen typically larger than liver (reversed from most other causes)

Mucocutaneous Leishmaniasis

• Tapir Nose: Complete destruction of nasal septum causing nasal collapse and characteristic "tapir-like" appearance
• Espundia: Brazilian Portuguese term for MCL
• Palatal Perforation: Visible hole in hard/soft palate
• Laryngeal Involvement: Hoarseness, stridor in advanced disease

---

3. Epidemiology

Geographic Distribution and Endemicity

Old World Leishmaniasis

• Mediterranean Basin: Southern Europe (Spain, Italy, Greece), North Africa (Morocco, Tunisia, Libya)
• Middle East: Syria, Iraq, Iran, Afghanistan, Saudi Arabia, Yemen
• Indian Subcontinent: India (Bihar state: 50% of global VL burden), Bangladesh, Nepal, Pakistan
• East Africa: Sudan, South Sudan, Ethiopia, Kenya, Somalia
• Central Asia: Uzbekistan, Turkmenistan

Predominant Species:

• Leishmania donovani (VL - anthroponotic)
• Leishmania infantum (VL - zoonotic, dogs as reservoir)
• Leishmania tropica (CL - urban, anthroponotic)
• Leishmania major (CL - rural, rodent reservoir)
• Leishmania aethiopica (CL - Ethiopia, Kenya; diffuse CL variant)

New World Leishmaniasis

• Central America: Mexico, Guatemala, Honduras, Belize, Costa Rica
• South America: Brazil (highest burden), Colombia, Peru, Bolivia, Venezuela, Ecuador
• Caribbean: Limited distribution

Predominant Species:

• Leishmania braziliensis (CL and MCL - high metastatic potential)
• Leishmania guyanensis (CL)
• Leishmania panamensis (CL)
• Leishmania mexicana (CL, rare chiclero's ulcer of ear)
• Leishmania amazonensis (CL, diffuse CL)
• Leishmania infantum/chagasi (VL) [1,2]

Vector Ecology

Sandfly Characteristics:

• Size: 2-3 mm (one-third the size of mosquitoes)
• Flight: Weak, short-range fliers (less than 200 meters from breeding sites)
• Behavior: Nocturnal biters; peak activity dusk to dawn
• Silence: Unlike mosquitoes, sandflies are silent fliers—victims unaware of bites
• Habitat: Prefer humid, dark environments; breed in organic-rich soil, animal burrows, tree holes, cracks in masonry
• Species:
  • Phlebotomus spp. (Old World)
  • Lutzomyia spp. (New World)
• Temperature Sensitivity: Activity increases 20-28°C; climate change expanding range

Only female sandflies transmit infection (require blood meals for egg development).

Transmission Patterns and Reservoirs

Anthroponotic Transmission

• Human-to-human cycle via sandfly vector
• No animal reservoir required
• Examples:
  • VL in Indian subcontinent (L. donovani)
  • Urban CL in Middle East (L. tropica)
• PKDL patients serve as long-term human reservoirs

Zoonotic Transmission

• Animal reservoirs maintain parasite in nature
• Spillover to humans via sandfly bites
• Reservoir hosts:
  • "Dogs: Most important for L. infantum (Mediterranean VL, New World VL)"
  • "Rodents: Desert rodents for L. major (rural CL)"
  • "Wild canids: Foxes, jackals"
  • "Sloths, marsupials: New World CL species"
• Canine Leishmaniasis: Major public health concern in endemic areas; infected dogs develop chronic disease with skin lesions harboring parasites

Other Transmission Routes (Rare)

• Congenital transmission: Documented in VL and HIV co-infection
• Blood transfusion: Case reports in endemic areas
• Needle-stick injury: Occupational exposure in laboratory settings
• Organ transplantation: Donor-derived infection
• Sexual transmission: Not documented [8]

Risk Factors and Vulnerable Populations

Individual Risk Factors:

• Occupational exposure: Military personnel, agricultural workers, construction workers, forest workers
• Outdoor sleeping: Lack of bed nets, inadequate housing
• Proximity to animals: Living with dogs (VL), proximity to rodent burrows (CL)
• Immunosuppression: HIV/AIDS, organ transplant recipients, immunosuppressive therapy, malnutrition
• Genetic susceptibility: HLA associations, IL-12 pathway polymorphisms

Population-Level Risk Factors:

• Poverty: Poor housing, malnutrition, limited access to healthcare
• Conflict and displacement: Population movement into endemic areas; deteriorating living conditions
• Urbanization: Periurban slums; human encroachment into sylvatic transmission cycles
• Deforestation: Environmental change bringing humans closer to reservoir hosts
• Climate change: Expanding sandfly habitats; altered seasonal patterns [1,2]

Epidemiological Trends

• VL Elimination Initiatives: Indian subcontinent targeted VL elimination by 2020 (delayed); significant progress with enhanced surveillance and treatment access
• Conflict-Related Outbreaks: Syrian crisis led to massive CL outbreak (> 100,000 cases)
• HIV Co-Infection: VL-HIV overlap zones in East Africa, Brazil, Mediterranean; bidirectional interaction worsening both diseases
• Climate-Driven Range Expansion: VL detected in previously non-endemic northern regions
• Drug Resistance: Emerging antimony resistance in Bihar, India necessitating policy change to liposomal amphotericin B [7]

---

4. Pathophysiology

Parasite Biology and Life Cycle

Leishmania are dimorphic protozoan parasites (Phylum Kinetoplastida) existing in two morphological forms:

1. Promastigote (Extracellular, Motile Form)

• Exists in sandfly gut and culture media
• 10-20 μm long, flagellated, spindle-shaped
• Multiplies by binary fission in sandfly midgut
• Differentiates into metacyclic promastigotes (infective stage) in sandfly proboscis
• Expresses surface glycoproteins (LPG - lipophosphoglycan) facilitating macrophage attachment

2. Amastigote (Intracellular, Non-Motile Form)

• Exists within mammalian macrophages
• 2-4 μm diameter, oval, aflagellate
• Also called LD bodies (Leishman-Donovan bodies) in histology
• Multiplies within phagolysosomes by binary fission
• Adapted to survive in acidic pH (4.5-5.0) and hydrolytic enzymes

Transmission Cycle

Step 1: Sandfly Feeding and Parasite Inoculation

• Female sandfly takes blood meal from infected host (human or animal)
• Ingests macrophages containing amastigotes
• In sandfly midgut: amastigotes transform to promastigotes
• Promastigotes multiply and migrate to proboscis
• During subsequent blood meal: metacyclic promastigotes inoculated into dermis along with sandfly saliva

Step 2: Infection of Mammalian Host

• Promastigotes phagocytosed by dermal macrophages, dendritic cells, neutrophils
• Opsonized by complement (C3b receptor-mediated uptake)
• Sandfly saliva contains vasodilatory, anti-hemostatic, and immunomodulatory molecules that enhance infection

Step 3: Intracellular Survival and Replication

• Within phagosome: promastigote transforms to amastigote (6-24 hours)
• Phagosome-lysosome fusion → creation of parasitophorous vacuole
• Amastigotes resist destruction via:
  • "LPG modification: Prevents lysosomal enzyme activation"
  • "Antioxidant enzymes: Neutralize reactive oxygen species"
  • "pH adaptation: Thrive in acidic environment"
  • "Protease inhibitors: Block macrophage proteolytic activity"
• Binary fission → 100-200 amastigotes per macrophage
• Cell rupture → release of amastigotes → infection of new macrophages

Step 4: Clinical Manifestation Determined by:

• Parasite species: Tropism for skin (L. tropica, L. major) vs viscera (L. donovani, L. infantum)
• Inoculum size: High inoculum favors disease progression
• Host immune response: Th1 (protective) vs Th2 (susceptibility) balance
• Vector factors: Sandfly saliva composition modulates immunity [8,9]

Immunopathogenesis

Protective Immunity: Th1-Mediated Response

CL Self-Healing and VL Resistance:

• IL-12 from dendritic cells and macrophages
• Th1 differentiation → IFN-γ and TNF-α production
• Macrophage activation → nitric oxide synthase (iNOS) expression
• Nitric oxide (NO) production → amastigote killing
• Cytotoxic T cells (CD8+): Direct killing of infected macrophages
• Development of immunological memory: Protection against reinfection

Chronic CL Lesions:

• Balance between parasite persistence and immune containment
• Localized granulomatous inflammation
• Eventual healing with scarring (months to 1-2 years)

Susceptibility: Th2-Mediated Response

VL Progression and Dissemination:

• IL-4, IL-10, IL-13 dominance
• Th2 differentiation → antibody production (ineffective against intracellular parasites)
• Suppression of macrophage activation
• Alternative macrophage activation (M2): Anti-inflammatory phenotype favors parasite survival
• Regulatory T cells (Tregs): Suppress protective Th1 responses
• Progressive parasite dissemination to reticuloendothelial organs

VL Pathology:

• Massive splenomegaly: Parasitized macrophages; extramedullary hematopoiesis
• Hepatomegaly: Kupffer cell hyperplasia; periportal inflammation
• Bone marrow infiltration: Parasitized macrophages replacing normal hematopoiesis → pancytopenia
• Lymphadenopathy: Generalized; more prominent in African VL
• Skin hyperpigmentation (Kala-Azar): Melanocyte stimulation; mechanism unclear

MCL Immunopathology

• Exaggerated Th1 response with tissue-destructive inflammation
• Delayed-type hypersensitivity reaction
• High IFN-γ and TNF-α → granulomatous inflammation
• Mucosal destruction despite low parasite burden ("immunopathology")
• Often follows inadequately treated CL or occurs years after apparent cure [9]

Species-Specific Pathogenesis

HIV Co-Infection: Synergistic Pathogenesis

• Bidirectional immune dysfunction: VL accelerates HIV progression; HIV promotes VL reactivation
• CD4+ T cell depletion: Loss of protective Th1 immunity
• Atypical presentations: Parasites in unusual sites (GI tract, lungs, skin)
• Treatment failure: > 50% with standard regimens
• Relapse rates: 60-90% in absence of ART and secondary prophylaxis
• Immune reconstitution inflammatory syndrome (IRIS): Paradoxical worsening after ART initiation [10]

---

5. Clinical Presentation

Cutaneous Leishmaniasis (CL)

Incubation Period

• Variable: Weeks to months (range 2 weeks to 2 years)
• Median: 2-3 months for L. tropica, L. major
• Longer incubation (6-12 months) possible for L. braziliensis

Evolution of Lesion

Stage 1: Papule (Early, 1-2 Weeks)

• Small, erythematous papule at bite site
• Asymptomatic or mild pruritus
• Easily overlooked

Stage 2: Nodule (2-8 Weeks)

• Enlarges to firm nodule (0.5-2 cm)
• Pink to violaceous color
• May show central scaling

Stage 3: Ulceration (2-6 Months)

• Central necrosis → painless ulcer
• Characteristic features:
  • Raised, indurated border ("volcano sign," "pizza-like edge")
  • Central granular base with seropurulent exudate
  • Round to oval shape
  • "Size: 1-10 cm (can be larger)"
• Surrounding erythema and induration
• Satellite papules/nodules in 10-20% of cases

Stage 4: Healing (Months to Years)

• Gradual re-epithelialization from periphery
• Leaves depressed, hypopigmented, atrophic scar
• Scarring can be cosmetically disfiguring, especially on face

Clinical Variants

Classical "Dry" vs "Wet" Cutaneous Leishmaniasis

• Dry CL (L. tropica): Single or few lesions; slow progression; chronic course (> 1 year); minimal exudate
• Wet CL (L. major): Multiple lesions; rapid evolution; abundant exudate; shorter course (3-6 months)

Sporotrichoid Leishmaniasis

• Linear nodules along lymphatic drainage
• Mimics sporotrichosis
• Due to L. braziliensis, L. guyanensis

Lupoid (Recidivans) Leishmaniasis

• Chronic, relapsing form around scar of healed CL
• Papules/nodules at periphery of scar
• Resembles lupus vulgaris
• Due to L. tropica; seen in Middle East

Diffuse Cutaneous Leishmaniasis (DCL)

• Rare anergic variant; absent cell-mediated immunity
• Widespread non-ulcerative nodules and plaques
• Resembles lepromatous leprosy
• Due to L. aethiopica (Africa), L. amazonensis, L. mexicana (Americas)
• Chronic, progressive; refractory to treatment

Chiclero's Ulcer

• CL of the ear pinna (cartilage destruction)
• Due to L. mexicana
• Occupational disease in "chicleros" (gum harvesters)

Number and Distribution of Lesions

• Single lesion: 50-70% of cases
• Multiple lesions (2-10): 20-40%
• Disseminated (> 10): 5-10%
• Exposed sites: Face, neck, arms, legs (sandfly access)
• Mucosal involvement at presentation: Rare (less than 1% for non-L. braziliensis)

Spontaneous Healing

• Old World CL: Most lesions heal spontaneously in 6-18 months
• New World CL: Variable; L. braziliensis may persist and metastasize to mucosa
• Factors favoring chronicity: Large lesions (> 5 cm), multiple lesions, immunosuppression, specific species (L. tropica, L. braziliensis)

Mucocutaneous Leishmaniasis (MCL)

Epidemiology

• Geographic restriction: Almost exclusively New World; 90% in Bolivia, Peru, Brazil
• Causative species: Primarily L. braziliensis (occasionally L. panamensis, L. guyanensis)
• Risk: 2-10% of L. braziliensis CL patients develop MCL (some studies report up to 40%)

Temporal Relationship

• Concurrent with CL: 10-20% of MCL cases
• Following CL healing: 80-90% of cases
  • "Latency period: Months to decades (median 2-5 years)"
  • Can occur despite adequate CL treatment

Clinical Features

Nasal Involvement (90%)

• Initial symptoms:
  • Nasal stuffiness/congestion
  • Rhinorrhea (serosanguineous)
  • Recurrent epistaxis
  • Crusting
• Progression:
  • Mucosal ulceration (erythematous, granular)
  • Septal perforation (hallmark finding)
  • Collapse of nasal cartilage → Tapir nose deformity
  • Alar rim destruction
• Late stage: Complete nasal destruction; facial disfigurement

Oropharyngeal Involvement (40-50%)

• Palatal ulceration and perforation
• Uvula destruction
• Pharyngeal ulceration
• Gingival and lip involvement

Laryngeal Involvement (10%)

• Hoarseness
• Dysphagia
• Stridor (airway obstruction)

Complications:

• Secondary bacterial infection
• Aspiration pneumonia
• Malnutrition (dysphagia)
• Severe psychosocial impact and stigma [4,5]

MCL Does NOT Heal Spontaneously → Requires systemic treatment

Visceral Leishmaniasis (Kala-Azar)

Incubation Period

• Range: 2-6 months (can be 10 days to years)
• Immunosuppressed patients: Shorter incubation

Classical Presentation (Gradual Onset)

Constitutional Symptoms

• Fever: Cardinal feature
  • Prolonged (weeks to months)
  • "Pattern: Irregular; double daily spikes characteristic"
  • Low-grade to high-grade (38-40°C)
  • Associated with rigors
• Weight loss: Progressive; cachexia in advanced disease
• Weakness and fatigue: Profound; bedridden in late stages
• Anorexia: Contributes to wasting

Abdominal Distension

• Massive splenomegaly: Hallmark of VL
  • Largest spleens in medicine (alongside myelofibrosis, malaria)
  • Extends across midline into right iliac fossa
  • Firm, non-tender
  • Enlarges progressively over months
• Hepatomegaly: Moderate; usually less prominent than spleen
• Ascites: Rare; suggests hypoalbuminemia or portal hypertension in severe cases

Skin Changes

• Kala-Azar (Black Fever): Hyperpigmentation
  • Affects hands, feet, abdomen, face
  • More prominent in dark-skinned individuals
  • "Mechanism: Increased melanocyte stimulation; unclear etiology"
  • Not always present
• Skin thinning: "Parchment-like" in cachexia

Lymphadenopathy

• Generalized in African VL (L. donovani MON-18, L. infantum)
• Less prominent in Indian VL

Hemorrhagic Manifestations (Advanced Disease)

• Petechiae, purpura
• Gingival bleeding, epistaxis
• GI bleeding (rare)
• Due to thrombocytopenia and coagulopathy

Physical Examination Findings

General Appearance

• Chronically ill, cachectic
• Pallor (severe anemia)
• Hyperpigmentation (variable)

Vital Signs

• Fever: Documented during examination or by history
• Tachycardia: Reflects anemia, fever
• Hypotension: Severe cases

Abdomen

• Splenomegaly: Massive (Hackett Grade IV-V in severe cases)
  • Measure below left costal margin in MCL and from xiphoid
• Hepatomegaly: 2-6 cm below RCM typically
• Ascites: Uncommon

Lymph Nodes

• Generalized lymphadenopathy (especially African VL)

Skin

• Hyperpigmentation, petechiae, purpura

Cardiovascular

• Tachycardia, flow murmurs (anemia)

No Focal Neurological Deficits (unless CNS opportunistic infection in HIV)

Laboratory Abnormalities (Characteristic Pancytopenia)

• Anemia: Normocytic, normochromic; Hb often less than 7 g/dL
• Leukopenia: WBC 2-3 x 10⁹/L; neutropenia
• Thrombocytopenia: Platelets less than 100 x 10⁹/L
• Hypoalbuminemia: Total protein elevated (hypergammaglobulinemia) but albumin low
• Hypergammaglobulinemia: Polyclonal; reversed albumin:globulin ratio (less than 1)
• Elevated liver enzymes: Mild to moderate
• Coagulopathy: Prolonged PT/APTT in advanced disease

VL in Special Populations

HIV Co-Infection

• Atypical presentations: Lack of fever or organomegaly
• Parasites in unusual sites: GI tract (causing diarrhea), lungs, skin
• Higher parasite burden in peripheral blood (can detect in buffy coat)
• Rapid progression; high mortality
• Relapse rates 60-90% without secondary prophylaxis [10]

Children

• More acute presentation
• Prominent lymphadenopathy
• Higher risk of bacterial co-infections

Elderly

• Subtle presentation; delayed diagnosis
• Comorbidities complicate management

Natural History and Prognosis

• Untreated VL: > 95% mortality within 2 years
  • "Death from: Severe anemia, hemorrhage, secondary infections (pneumonia, tuberculosis, dysentery), multi-organ failure"
• Treated VL: Cure rates > 90% with appropriate therapy
  • Early treatment critical to prevent irreversible complications

Post-Kala-Azar Dermal Leishmaniasis (PKDL)

Definition

• Cutaneous manifestation occurring after successful treatment of VL
• Not a relapse of VL (visceral disease resolved)
• Dermatological sequelae with significant epidemiological importance

Epidemiology

• Indian subcontinent (L. donovani): 5-15% of treated VL patients
  • "Latency: 6 months to 3 years post-VL treatment (median 2 years)"
• East Africa (Sudan): 50-60% of VL patients
  • "Latency: During or shortly after VL treatment (paradoxical)"

Clinical Features

Skin Lesions (Polymorphic)

• Hypopigmented macules: Most common; discrete or confluent
• Erythematous macules and papules
• Nodules: Firm; may coalesce
• Distribution:
  • Face (perioral, perinasal)
  • Trunk, upper limbs
  • Generalized in severe cases
• Evolution: Progresses over months to years
• No systemic symptoms: Afebrile, no organomegaly

Variants

• Polymorphic: Macules, papules, nodules coexist (most common)
• Macular: Hypopigmented macules only
• Papular/Nodular: Resembles lepromatous leprosy

Pathogenesis

• Immune reconstitution: Restoration of Th1 response exposes residual parasites in skin
• Persistent antigen: Low parasite burden in dermis
• T cell-mediated inflammation: Granuloma formation

Public Health Significance

• PKDL patients are infectious reservoirs: Sandflies can acquire infection from skin lesions
• Contributes to ongoing anthroponotic transmission
• Complicates VL elimination efforts in Indian subcontinent

Diagnosis

• Clinical diagnosis (characteristic rash after treated VL)
• Skin biopsy: Histology and PCR (parasites may be scanty)
• Serology: May remain positive from prior VL

Treatment

• Indian PKDL: Often self-resolves in 1-3 years, but treatment recommended to reduce transmission
  • "Miltefosine: 12 weeks"
  • "Liposomal amphotericin B: Multiple doses"
• African PKDL: More aggressive; requires treatment
  • "Sodium stibogluconate: 2 months or longer [11]"

---

6. Clinical Examination

Dermatological Examination (CL/MCL)

Skin Inspection

1. Lesion characteristics:
   • Size, shape, color
   • Ulceration: Central crater, raised border
   • Base: Granular, purulent, necrotic
   • Surrounding skin: Erythema, induration, satellite lesions
2. Number and distribution: Single vs multiple; anatomic sites
3. Scarring: Evidence of healed lesions (hypopigmented, atrophic)

ENT Examination (Essential if New World CL or Suspected MCL)

1. Anterior rhinoscopy:
   • Nasal mucosa: Erythema, ulceration, crusting
   • Septal integrity: Perforation (pathognomonic for MCL)
   • Turbinate involvement
2. Oropharynx:
   • Palatal ulceration or perforation
   • Uvula, pharyngeal wall lesions
3. Laryngoscopy (if hoarseness): Vocal cord involvement

Lymph Nodes

• Regional lymphadenopathy (draining lesion)
• Sporotrichoid pattern: Linear nodules

Systemic Examination (VL)

General Inspection

• Cachexia, pallor, hyperpigmentation
• Assess nutritional status

Abdominal Examination

1. Inspection: Distension (organomegaly, ascites)
2. Palpation:
   • Spleen: Measure from left costal margin (MCL) and from xiphoid
     • Grade using Hackett scale (I-V based on extent)
     • Massive splenomegaly: Crossing midline
   • Liver: Measure from right costal margin
   • Hepatosplenomegaly ratio: Spleen typically larger
3. Percussion: Confirm organomegaly
4. Ascites: Shifting dullness (rare)

Lymphadenopathy

• Generalized (especially African VL)
• Cervical, axillary, inguinal

Skin

• Hyperpigmentation (hands, feet, face, abdomen)
• Hemorrhagic manifestations: Petechiae, purpura

Cardiovascular

• Tachycardia, flow murmurs (anemia)

Respiratory

• Signs of pneumonia (common co-infection)

---

7. Investigations

Parasitological Diagnosis (Gold Standard)

Cutaneous and Mucocutaneous Leishmaniasis

1. Skin Slit Smear

• Technique:
  • Clean ulcer base; remove crust
  • Make small incision at indurated edge
  • Scrape dermal layer (parasites in macrophages, not exudate)
  • Smear on glass slide; air dry
• Staining: Giemsa or Wright stain
• Microscopy: Identify amastigotes (LD bodies) within macrophages
  • 2-4 μm oval bodies
  • Nucleus and kinetoplast (rod-shaped, perpendicular)
• Sensitivity: 40-70% (varies by species, lesion age)

2. Skin Biopsy

• Indications: Slit smear negative; atypical presentation; differential diagnosis
• Technique: Punch biopsy (3-4 mm) from ulcer edge
• Histology:
  • Granulomatous inflammation
  • Amastigotes in macrophages (may be scanty)
• Ancillary tests: PCR, culture (see below)
• Sensitivity: 50-80%

3. Mucosal Biopsy (MCL)

• Nasal or palatal biopsy (under ENT guidance)
• Low parasite burden in MCL → often negative microscopy
• PCR essential for confirmation

Visceral Leishmaniasis

1. Splenic Aspirate

• Gold standard: > 95% sensitivity
• Technique: Percutaneous needle aspiration under ultrasound or CT guidance
• Risks:
  • Hemorrhage (1-10% significant bleeding; 0.1% fatal)
  • "Contraindicated if: Severe coagulopathy, platelet less than 40,000/μL, uncooperative patient"
• Microscopy: Giemsa-stained smears; abundant amastigotes
• Use: Limited to specialized centers with expertise

2. Bone Marrow Aspirate

• Safer alternative to splenic aspirate
• Technique: Sternal or iliac crest aspiration
• Sensitivity: 60-85% (lower than spleen)
• Microscopy: Amastigotes in macrophages; may see hemophagocytosis
• Advantages: Low complication rate; widely available

3. Lymph Node Aspirate

• African VL (prominent lymphadenopathy)
• Sensitivity: 50-60%

4. Peripheral Blood

• Low sensitivity in immunocompetent VL
• Higher sensitivity in HIV co-infection: Buffy coat smears may show amastigates (high parasitemia)

Molecular Diagnosis (PCR)

Advantages:

• High sensitivity and specificity: > 95% for most samples
• Species identification: Differentiate Leishmania species (important for treatment, prognosis)
• Non-invasive samples: Blood, skin scrapings (less invasive than tissue biopsy)

Applications:

• CL: Skin slit smear or biopsy
• MCL: Mucosal biopsy (critical given low parasite burden)
• VL: Blood, bone marrow, splenic aspirate
• PKDL: Skin biopsy

Limitations:

• Not widely available in resource-limited endemic settings
• Cost
• Cannot distinguish active infection from past exposure (DNA persistence)

PCR Targets:

• Kinetoplast DNA (kDNA): Minicircles (high copy number → high sensitivity)
• rRNA genes, GP63, ITS1

Serological Tests

Advantages:

• Non-invasive
• Rapid results

Limitations:

• Cannot distinguish active from past infection: Antibodies persist months to years
• Cross-reactivity: Other kinetoplastids (Trypanosoma), chronic infectious diseases
• Low sensitivity in CL and immunosuppressed VL

VL-Specific Serology

1. rK39 Rapid Diagnostic Test (RDT)

• Point-of-care immunochromatographic dipstick
• Antigen: rK39 (39-amino acid repeat of kinesin-related protein)
• Performance:
  • "Sensitivity: 90-95% (Indian subcontinent, East Africa)"
  • Lower sensitivity in Mediterranean, Brazil (70-80%)
  • "Specificity: 85-95%"
• Advantages: Rapid (10-20 minutes), minimal training, field deployment
• Limitations: Remains positive after cure; false positives in endemic areas
• WHO-recommended for VL diagnosis in resource-limited settings [12]

2. Direct Agglutination Test (DAT)

• Antigen: Whole, stained promastigotes
• Performance: Sensitivity 95-98%; Specificity 90-95%
• Advantages: High accuracy; affordable
• Limitations: Requires laboratory; 18-hour incubation; remains positive post-treatment

3. ELISA (Enzyme-Linked Immunosorbent Assay)

• Antigen: Crude or recombinant Leishmania antigens
• Sensitivity: 90-95%; Specificity: 80-90%
• Research and reference laboratories

4. Immunofluorescence Antibody Test (IFAT)

• Older method; less used currently
• Sensitivity: 85-95%

CL/MCL Serology

• Limited utility: Low sensitivity (less than 50%)
• Exceptions: MCL (higher antibody titers) → serology may support diagnosis

Culture

Advantages:

• Parasite isolation for species identification, drug susceptibility testing, research

Media:

• Novy-MacNeal-Nicolle (NNN) medium (biphasic)
• Schneider's insect medium (liquid)

Technique:

• Inoculate aspirate/biopsy into culture media
• Incubate at 22-26°C (promastigote growth)
• Monitor weekly for promastigote growth (2-4 weeks)

Limitations:

• Slow (weeks)
• Contamination risk
• Lower sensitivity than PCR (60-80%)
• Specialized laboratories

Histopathology

CL:

• Granulomatous dermatitis
• Amastigotes in macrophages (variable number)
• Differential: Sarcoidosis, tuberculosis, fungal infections

MCL:

• Granulomatous inflammation
• Few or no parasites (immunopathology-driven)
• Requires PCR for confirmation

VL:

• Bone marrow/spleen: Parasitized macrophages; hemophagocytosis
• Liver: Kupffer cell hyperplasia; amastigotes in Kupffer cells

Supportive Laboratory Investigations (VL)

Complete Blood Count:

• Pancytopenia (hallmark)
  • "Anemia: Hb 6-9 g/dL (normocytic, normochromic)"
  • "Leukopenia: WBC 2-3 x 10⁹/L"
  • "Thrombocytopenia: Platelets 50-100 x 10⁹/L"

Biochemistry:

• Hypoalbuminemia: less than 3 g/dL
• Hypergammaglobulinemia: Total protein elevated (8-10 g/dL), but albumin low
• Reversed A:G ratio (less than 1)
• Elevated transaminases (mild)
• Elevated alkaline phosphatase

Coagulation:

• Prolonged PT/APTT (severe disease, hepatic dysfunction)

Inflammatory Markers:

• Elevated ESR, CRP

HIV Testing:

• Mandatory in all VL cases (high co-infection rates in certain regions)

---

8. Management

General Principle: All suspected leishmaniasis should be discussed with Infectious Diseases specialist or Tropical Medicine expert. Treatment choice depends on:

• Leishmania species
• Clinical form (CL vs MCL vs VL)
• Geographic origin
• Patient factors (pregnancy, renal/hepatic function, HIV status)
• Local drug resistance patterns

Cutaneous Leishmaniasis

Indications for Treatment

Treat if:

• Multiple lesions (> 5)
• Large lesions (> 4 cm)
• Lesion duration > 6 months without healing
• Facial lesions (cosmetic concern)
• Lesions near mucosal sites (risk of MCL)
• L. braziliensis infection (high MCL risk)
• Immunocompromised host
• Patient preference (cosmetic, social)

Observation may be appropriate if:

• Single, small lesion (less than 4 cm)
• Old World CL (L. major, L. tropica) in immunocompetent patient
• No involvement of face or areas near mucosa
• Evidence of healing (re-epithelialization)
• Patient accepting of scar

Local Therapies (Mild CL)

1. Cryotherapy (Liquid Nitrogen)

• Mechanism: Tissue destruction; reduction of parasite load
• Technique: Apply liquid nitrogen to lesion and 2 mm surrounding skin; 10-30 seconds; repeat weekly x 2-6 weeks
• Efficacy: 60-90% cure (variable by species, lesion characteristics)
• Indications: Small (less than 3 cm), uncomplicated Old World CL
• Advantages: Simple, safe, inexpensive
• Disadvantages: Multiple sessions; painful; scarring

2. Intralesional Pentavalent Antimonials

• Drug: Sodium stibogluconate or meglumine antimoniate
• Dose: Infiltrate lesion(s) with 0.2-2 mL (depends on lesion size) every 3-7 days x 3-8 injections
• Efficacy: 70-85% cure
• Indications: Limited CL (few small lesions)
• Advantages: High local drug concentration; reduced systemic toxicity
• Disadvantages: Painful; requires multiple visits [13]

3. Topical Paromomycin

• Formulation: 15% paromomycin + 12% methylbenzethonium chloride (vehicle enhances penetration)
• Application: Apply twice daily x 10-20 days
• Efficacy: Variable (40-80%); better for Old World CL
• Indications: Superficial, small lesions
• Advantages: Non-invasive; self-administered
• Disadvantages: Variable efficacy; local irritation; not available in all countries

4. Thermotherapy

• Mechanism: Heat-induced parasite killing (50-53°C for 30 seconds)
• Efficacy: 60-70% for Old World CL
• Advantages: Single session; no drug toxicity
• Disadvantages: Requires specialized device; painful; limited availability

Systemic Therapies (Complex CL, MCL, VL)

1. Liposomal Amphotericin B (AmBisome)

• Mechanism: Binds to ergosterol in parasite membrane → pore formation → cell death
• Advantages:
  • "High efficacy: > 90% cure for VL; 85-95% for MCL"
  • Reduced toxicity compared to conventional amphotericin B (liposomal encapsulation targets reticuloendothelial system)
  • Shorter treatment for VL (single or few doses in India)
• Dosing:
  • "VL (Indian subcontinent): 10 mg/kg single dose IV (WHO-recommended since 2010)"
  • "VL (East Africa, Brazil, Mediterranean): 3-5 mg/kg/day x 5-10 days OR 3 mg/kg on days 1-5, 14, 21 (total 18-21 mg/kg)"
  • "MCL: 2-3 mg/kg/day x 7-10 days OR total cumulative dose 20-40 mg/kg"
  • "CL: Not first-line; reserved for refractory cases"
• Adverse Effects:
  • "Infusion-related: Fever, chills, hypotension, nausea (premedicate with paracetamol, antihistamine)"
  • "Nephrotoxicity: Monitor creatinine (less than conventional amphotericin B)"
  • "Electrolyte abnormalities: Hypokalemia, hypomagnesemia (monitor and replace)"
  • "Hepatotoxicity: Monitor LFTs"
• Contraindications: Hypersensitivity
• Pregnancy: Category B; use if benefit outweighs risk
• Cost: Expensive; WHO negotiated price reduction for endemic countries [14]

2. Miltefosine

• Mechanism: Alkylphosphocholine; disrupts cell membrane signaling and synthesis; induces apoptosis
• Historical significance: First effective oral drug for leishmaniasis (approved 2002)
• Dosing:
  • "Adults: 50 mg (if less than 25 kg) or 100 mg (if ≥25 kg) PO once daily x 28 days"
  • "VL: Standard 28-day course"
  • "CL/MCL: 28 days (some protocols extend to 42-90 days for MCL)"
• Efficacy:
  • "VL (India): 95% cure initially; declining efficacy noted (emerging resistance concerns)"
  • "VL (Africa): Lower efficacy (60-70%); not recommended as monotherapy"
  • "MCL: 70-80% cure"
  • "CL: Variable (60-80%)"
• Adverse Effects:
  • "GI disturbances (most common): Nausea, vomiting, diarrhea (take with food to minimize)"
  • Transaminase elevation (reversible)
  • Nephrotoxicity (monitor creatinine)
  • "Teratogenicity: Category D; Contraindicated in pregnancy"
  • Contraception required for women of childbearing potential during and 3 months after treatment
• Advantages: Oral; outpatient treatment; relatively safe
• Disadvantages: Long course; GI side effects; teratogenicity; emerging resistance [15]

3. Pentavalent Antimonials (Sodium Stibogluconate, Meglumine Antimoniate)

• Historical: Mainstay for decades (since 1940s)
• Mechanism: Prodrug; converted to trivalent antimony (active form); inhibits parasite glycolysis and fatty acid oxidation
• Dosing:
  • 20 mg/kg/day (based on antimony content) IM or IV x 20-30 days
  • "VL: 28-30 days"
  • "MCL: 28-30 days (some protocols 42 days)"
  • "CL: 10-20 days"
• Efficacy:
  • "VL (India): High resistance (> 60% failure) → No longer recommended in Bihar"
  • "VL (Africa, Brazil): Still effective (85-95%)"
  • "MCL: 70-85% cure"
  • "CL: 60-90% (variable by species)"
• Adverse Effects (Dose-Dependent; Frequent):
  • "Cardiotoxicity (most serious): QTc prolongation, arrhythmias, sudden death"
    • ECG monitoring required: Baseline and weekly during treatment
    • Discontinue if QTc > 500 ms
  • "Pancreatitis: Elevated amylase/lipase (common); clinical pancreatitis (1-5%)"
  • "Hepatotoxicity: Elevated transaminases"
  • "Nephrotoxicity: Elevated creatinine"
  • Arthralgias, myalgias
  • Injection site pain (IM)
  • Nausea, vomiting, headache
• Contraindications:
  • Pregnancy (Category C; use only if no alternative)
  • Cardiac disease
  • Renal/hepatic impairment
  • Concurrent QT-prolonging drugs
• Advantages: Effective in many regions (outside Bihar); parenteral formulation useful for directly observed therapy
• Disadvantages: Toxicity profile; resistance in India; requires prolonged course and monitoring [8]

4. Paromomycin (Aminosidine)

• Mechanism: Aminoglycoside antibiotic; inhibits parasite protein synthesis
• Dosing:
  • "VL: 15 mg/kg/day IM x 21 days (used in India, East Africa)"
  • Often combined with other drugs (see combination therapy below)
• Efficacy:
  • "VL monotherapy: 85-95% (Africa); lower in India"
  • "Combination therapy: Synergistic with antimonials or miltefosine"
• Adverse Effects:
  • "Ototoxicity (tinnitus, hearing loss): Monitor audiology"
  • "Nephrotoxicity: Monitor creatinine"
  • Injection site pain
• Advantages: Affordable; shorter course than antimonials
• Disadvantages: Parenteral; toxicity monitoring required; not registered in all countries

5. Pentamidine

• Mechanism: Interferes with parasite DNA, RNA, protein synthesis
• Indications: Limited role; second-line for antimony-resistant New World CL
• Dosing: 2-4 mg/kg IM every other day or weekly x 4-7 doses
• Efficacy: 70-85% for CL due to L. guyanensis; less effective for other species
• Adverse Effects:
  • Hypoglycemia (life-threatening; monitor glucose)
  • Diabetes mellitus (irreversible pancreatic damage)
  • Hypotension
  • Nephrotoxicity
  • Arrhythmias
• Advantages: Effective for some antimony-resistant CL
• Disadvantages: Severe toxicity profile; requires close monitoring; not for VL

Combination Therapy (VL)

Rationale:

• Shorten treatment duration
• Reduce toxicity (lower doses, shorter exposure)
• Improve adherence
• Reduce emergence of drug resistance
• Cost-effectiveness

WHO-Recommended Combinations:

Indian Subcontinent VL (Immunocompetent):

• First-line: Liposomal amphotericin B 10 mg/kg single dose (> 95% cure)
• Alternative: Combination regimens:
  • Liposomal amphotericin B (5 mg/kg single dose) + Miltefosine (7 days)
  • Liposomal amphotericin B (5 mg/kg single dose) + Paromomycin (10 days)

East Africa VL:

• First-line combinations:
  • "Sodium stibogluconate + Paromomycin (17 days): 85-90% cure; shorter than monotherapy"
  • Liposomal amphotericin B + Paromomycin
  • Liposomal amphotericin B + Miltefosine

VL in HIV Co-Infection:

• Initial treatment: Liposomal amphotericin B (total 30-40 mg/kg) + antiretroviral therapy (ART)
• Secondary prophylaxis (prevent relapse): Pentavalent antimonials (monthly) or Liposomal amphotericin B (monthly) until CD4 > 200 cells/μL for 6 months [10,16]

Mucocutaneous Leishmaniasis

• Always requires systemic treatment (local therapies ineffective)
• First-line:
  • Liposomal Amphotericin B (total 20-40 mg/kg)
  • Pentavalent Antimonials (20 mg/kg/day x 28-30 days; some protocols 42 days)
• Second-line: Miltefosine (28 days; some extend to 42-90 days)
• Cure rates: 70-90% (lower than VL; immunopathology component)
• Relapses common: Long-term follow-up required
• Adjunctive measures:
  • ENT assessment and management
  • Surgical debridement (post-treatment for residual tissue damage)
  • Psychosocial support (disfigurement stigma) [5]

Post-Kala-Azar Dermal Leishmaniasis (PKDL)

• Treatment recommended to reduce transmission (especially Indian PKDL)
• Indian PKDL:
  • Miltefosine (12 weeks)
  • Liposomal Amphotericin B (2.5 mg/kg on days 0, 1, 2, 3, 4, 10, 17, 24, 31, 38; total 12.5 mg/kg)
  • "Cure: 70-90%"
• African PKDL:
  • Sodium stibogluconate (2-4 months)
  • More aggressive treatment required [11]

Supportive Care and Monitoring

VL Management:

• Admit to hospital: Severe disease, complications, need for IV therapy
• Nutritional support: High-protein, high-calorie diet; correct malnutrition
• Transfusions: RBC transfusion for severe anemia (Hb less than 7 g/dL symptomatic); platelet transfusion for active bleeding with severe thrombocytopenia
• Antimicrobial therapy: Treat bacterial co-infections (pneumonia common)
• Monitoring during treatment:
  • "Weekly: CBC, renal function, LFTs"
  • "ECG (if antimonials): Baseline and weekly"
  • Glucose monitoring (if pentamidine)
  • "Clinical assessment: Fever resolution, spleen regression, weight gain"

CL/MCL:

• Wound care for ulcers (keep clean, prevent secondary infection)
• Pain management
• Psychological support (stigma, disfigurement)

Prevention and Control

Individual Protection:

• Vector avoidance:
  • Insecticide-treated bed nets (ITNs)
  • Insect repellents (DEET, permethrin-treated clothing)
  • Avoid outdoor activities dusk to dawn in endemic areas
  • Long sleeves, long pants
• Traveler precautions: Pre-travel consultation; post-travel screening if exposed

Public Health Interventions:

• Vector control: Residual insecticide spraying; environmental management (remove organic debris, animal burdens)
• Reservoir control:
  • "Canine leishmaniasis: Dog screening and treatment (controversial; culling vs treatment); insecticide-treated dog collars"
  • Rodent control (rural CL)
• Case detection and treatment: Active and passive surveillance; improve access to diagnosis and treatment
• Health education: Community awareness; reduce stigma

VL Elimination Programs:

• Indian subcontinent initiative: Enhanced surveillance, rapid diagnostics (rK39 RDT), free treatment (liposomal amphotericin B), vector control, PKDL management
• Kala-Azar Elimination Program target: less than 1 case/10,000 population at block level by 2020 (extended due to delays) [17]

No Vaccine Currently Available:

• Research ongoing (candidate vaccines in trials)

---

9. Complications

Visceral Leishmaniasis

Hematological:

• Severe anemia → heart failure, fatigue
• Neutropenia → recurrent bacterial infections (pneumonia, sepsis)
• Thrombocytopenia → hemorrhage (GI bleeding, epistaxis, purpura)

Infectious:

• Bacterial co-infections (most common cause of death):
  • Pneumonia (Streptococcus pneumoniae, Staphylococcus aureus, gram-negatives)
  • Septicemia
  • Tuberculosis (common in endemic areas)
  • Dysentery
• Opportunistic infections in HIV co-infection

Hepatosplenic:

• Portal hypertension (rare)
• Splenic rupture (rare, spontaneous or traumatic)
• Hepatic dysfunction

Renal:

• Glomerulonephritis (immune complex-mediated)
• Acute kidney injury (dehydration, sepsis, drug toxicity)

Cardiovascular:

• Anemia-related heart failure
• Myocarditis (rare)

Nutritional:

• Severe malnutrition, cachexia
• Vitamin deficiencies

Treatment-Related:

• Drug toxicities (cardiotoxicity, nephrotoxicity, hepatotoxicity, pancreatitis)
• Amphotericin B infusion reactions
• Hypoglycemia (pentamidine)

VL-HIV Co-Infection:

• Accelerated HIV progression
• Atypical presentations; disseminated disease
• High relapse rates (60-90% without secondary prophylaxis)
• Treatment failure [10]

Cutaneous and Mucocutaneous Leishmaniasis

CL:

• Scarring: Atrophic, hypopigmented scars; cosmetic disfigurement
• Stigma: Psychosocial impact (particularly facial scars)
• Secondary bacterial infection: Ulcer superinfection
• Sporotrichoid spread: Lymphatic dissemination
• Diffuse CL: In anergic patients (rare)
• Progression to MCL: Particularly L. braziliensis (2-40%)

MCL:

• Facial disfigurement: Nasal collapse, palatal destruction
• Airway obstruction: Laryngeal involvement
• Aspiration pneumonia: Dysphagia
• Malnutrition: Difficulty eating
• Severe psychosocial impact: Stigma, isolation, depression [4]

---

10. Prognosis and Outcomes

Cutaneous Leishmaniasis

• Spontaneous healing: 50-90% (Old World CL) over 6-18 months
• Treatment response: 70-95% cure (depends on therapy, species)
• Scarring: Universal; cosmetic concern
• Recurrence: 5-15% (especially lupoid leishmaniasis)
• Progression to MCL: 2-10% (L. braziliensis); rare for Old World species
• Quality of life: Stigma and psychosocial impact significant [3,4]

Mucocutaneous Leishmaniasis

• Untreated: Progressive destruction; no spontaneous healing
• Treatment response: 70-90% cure
• Relapses: 10-30% (higher than CL or VL)
• Residual disfigurement: Common despite treatment
• Long-term follow-up: Required; relapses may occur years later
• Quality of life: Severe impact due to disfigurement [5]

Visceral Leishmaniasis

• Untreated: > 95% mortality within 2 years
• Treated (immunocompetent): > 90% cure with appropriate therapy
• Mortality (treated): 5-10% (higher in severe disease, delayed diagnosis, bacterial co-infections)
• PKDL development: 5-15% (Indian subcontinent); 50-60% (East Africa)
• Relapse (immunocompetent): less than 5% with adequate treatment
• VL-HIV co-infection:
  • "Treatment failure: > 50% with standard regimens"
  • "Relapse: 60-90% without secondary prophylaxis"
  • "Mortality: 20-30% despite treatment [6,7,10]"

Prognostic Factors

Poor Prognosis (VL):

• Age extremes (very young, elderly)
• Severe malnutrition
• Delayed diagnosis
• Severe pancytopenia (Hb less than 5 g/dL, platelets less than 20,000)
• Hemorrhage
• Bacterial co-infections
• HIV co-infection
• Jaundice
• Renal impairment

Good Prognosis:

• Early diagnosis and treatment
• Immunocompetent host
• Appropriate drug choice
• Access to supportive care

---

11. Evidence and Guidelines

International Guidelines

WHO Guidelines:

• Control of the Leishmaniases (WHO Technical Report Series 949, 2010): Comprehensive global guidelines for diagnosis, treatment, and control
• Regional treatment guidelines: Specific recommendations for Indian subcontinent, East Africa, Mediterranean, Americas
• VL elimination strategy: Target less than 1 case/10,000 population

Infectious Diseases Society of America (IDSA):

• Clinical Practice Guidelines for the Treatment of Leishmaniasis (published in Clinical Infectious Diseases): Evidence-based recommendations for North American clinicians managing imported leishmaniasis

Pan American Health Organization (PAHO):

• Guidelines for New World leishmaniasis (CL, MCL, VL in Americas)

European Guidelines:

• Recommendations for Mediterranean leishmaniasis and imported cases

Key Evidence Base

Liposomal Amphotericin B for VL:

• Multiple RCTs demonstrating > 90% efficacy
• Single-dose regimen (10 mg/kg) validated in Indian subcontinent (non-inferiority trials)
• Cost-effectiveness analyses supporting WHO recommendation [14]

Combination Therapy for VL:

• RCTs showing non-inferiority of short-course combinations vs. monotherapy (Indian subcontinent, East Africa)
• Reduced treatment duration, improved adherence, cost savings [16]

Miltefosine:

• Phase III trials establishing efficacy for VL, CL, MCL
• Post-marketing surveillance detecting declining efficacy and resistance concerns in India [15]

Pentavalent Antimonials:

• Decades of observational data
• Resistance documented in Bihar, India (> 60% failure rates) prompting policy change
• Still effective in other regions [8]

Systematic Reviews:

• Cochrane reviews on interventions for CL, MCL [5,13]
• Meta-analyses on treatment outcomes, adverse events [18,19]

---

12. Patient and Layperson Explanation

What is Leishmaniasis?

Leishmaniasis is an infection caused by tiny parasites that are spread through the bite of small flies called sandflies. These flies are found in tropical and subtropical countries around the world, especially in poor communities.

Where Can You Catch It?

You can get leishmaniasis in many parts of the world, including:

• The Middle East (countries like Afghanistan, Iraq, Syria)
• Parts of South America (Brazil, Colombia, Peru)
• India and nearby countries
• Parts of Africa

Sandflies are very small (much smaller than mosquitoes) and fly silently, so you may not even know you've been bitten. They usually bite at night.

What Are the Different Types?

There are three main types of leishmaniasis:

1. Skin Leishmaniasis (Cutaneous Leishmaniasis) This is the most common type. It causes a sore on the skin where the sandfly bit you. The sore looks like a volcano—raised edges with a hole in the middle. It doesn't usually hurt. After many months, the sore heals by itself, but it leaves a scar.

2. Nose and Mouth Leishmaniasis (Mucocutaneous Leishmaniasis) This is a more serious type that affects the inside of your nose and mouth. It can destroy the tissue inside your nose and create holes in your palate (roof of mouth). This type does not heal on its own and needs strong treatment. It can cause severe disfigurement if not treated.

3. Internal Leishmaniasis (Visceral Leishmaniasis or Kala-Azar) This is the most dangerous type. The parasites travel to your liver, spleen, and bone marrow. You get:

• Fever that lasts for weeks or months
• A very swollen belly (because your spleen gets huge)
• Weight loss and weakness
• Pale skin (anemia)

If not treated, this type is almost always fatal. But with proper treatment, most people can be cured.

How Is It Treated?

Treatment depends on which type you have:

For simple skin sores:

• We might freeze the sore with liquid nitrogen
• Or inject medicine directly into the sore

For serious skin disease, nose/mouth disease, or internal disease:

• We use strong anti-parasite medicines
• The main treatment is a medicine called Amphotericin B, given through a drip (IV) in the hospital
• Another option is a pill called Miltefosine that you take for about a month
• Treatment works very well when given promptly

Can It Be Prevented?

There's no vaccine yet, but you can reduce your risk:

• Use bed nets treated with insecticide when sleeping in areas where sandflies live
• Wear long sleeves and long pants in the evening and at night
• Use insect repellent
• Avoid sleeping outdoors in areas where the disease is common

Important Message

If you've traveled to a country where leishmaniasis is found and you develop a skin sore that doesn't heal, or if you have ongoing fever and a swollen belly, see a doctor. Early treatment prevents serious complications and saves lives.

---

13. References

1. Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671. doi:10.1371/journal.pone.0035671

2. Zhang SX, Wang J, Li HY, et al. Global, regional, and national burden of Visceral leishmaniasis, 1990-2021: findings from the global burden of disease study 2021. Parasit Vectors. 2025;18(1):207. doi:10.1186/s13071-025-06796-x

3. van Griensven J, Gadisa E, Aseffa A, et al. Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic Review. PLoS Negl Trop Dis. 2016;10(3):e0004495. doi:10.1371/journal.pntd.0004495

4. Nuwangi H, Ranasinghe S, Noordeen F. Stigma associated with cutaneous and mucocutaneous leishmaniasis: A systematic review. PLoS Negl Trop Dis. 2023;17(12):e0011818. doi:10.1371/journal.pntd.0011818

5. Amato VS, Tuon FF, Bacha HA, et al. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg. 2007;77(2):266-274.

6. Singh-Phulgenda S, Camara Y, Kip AE, et al. Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2021;15(3):e0009302. doi:10.1371/journal.pntd.0009302

7. Gebreyohannes EA, Bhagvathula AS, Abegaz TM, et al. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis. Infect Dis Poverty. 2018;7(1):108. doi:10.1186/s40249-018-0491-7

8. Berbert TRN, Mello TFP, Manduca JNL, et al. Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review. Dermatol Res Pract. 2018;2018:9014726. doi:10.1155/2018/9014726

9. Meireles CB, Maia LC, Soares GC, et al. Atypical presentations of cutaneous leishmaniasis: A systematic review. Acta Trop. 2017;172:240-254. doi:10.1016/j.actatropica.2017.05.022

10. Cota GF, de Sousa MR, de Mendonça AL, et al. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis. 2013;7(5):e2195. doi:10.1371/journal.pntd.0002195

11. Sunyoto T, Boelaert M, Meheus F, et al. Uncharted territory of the epidemiological burden of cutaneous leishmaniasis in sub-Saharan Africa—A systematic review. PLoS Negl Trop Dis. 2018;12(10):e0006914. doi:10.1371/journal.pntd.0006914

12. Sundar S, Singh OP. Molecular Diagnosis of Visceral Leishmaniasis. Mol Diagn Ther. 2018;22(4):443-457. doi:10.1007/s40291-018-0343-y

13. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS One. 2017;12(9):e0184777. doi:10.1371/journal.pone.0184777

14. Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother. 2013;14(1):53-63. doi:10.1517/14656566.2013.755515

15. Uribe-Restrepo A, Cossio A, Desai MM, et al. Interventions to treat cutaneous leishmaniasis in children: A systematic review. PLoS Negl Trop Dis. 2018;12(12):e0006986. doi:10.1371/journal.pntd.0006986

16. Galvão EL, Pedras MJ, Cota GF, et al. Efficacy of azole therapy for tegumentary leishmaniasis: A systematic review and meta-analysis. PLoS One. 2017;12(10):e0186117. doi:10.1371/journal.pone.0186117

17. Blaizot R, Nabet C, Videau M, et al. Cutaneous leishmaniasis in sub-Saharan Africa: a systematic review of Leishmania species, vectors and reservoirs. Parasit Vectors. 2024;17(1):303. doi:10.1186/s13071-024-06381-8

18. Nery RLA, Starke-Buzetti WA, Hiramoto RM, et al. Leishmania spp. genetic factors associated with cutaneous leishmaniasis antimony pentavalent drug resistance: a systematic review. Mem Inst Oswaldo Cruz. 2024;119:e230240. doi:10.1590/0074-02760230240

19. Cota GF, de Sousa MR, Fereguetti TO, et al. The Cure Rate after Placebo or No Therapy in American Cutaneous Leishmaniasis: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(2):e0149697. doi:10.1371/journal.pone.0149697

20. Vieira-Duarte R, Rocha M, Geiger SM, et al. Mortality due to visceral leishmaniasis in Brazil by municipalities, 2001-2018: a spatial-temporal analysis of estimates from the Global Burden of Disease study. Public Health. 2024;234:170-176. doi:10.1016/j.puhe.2024.06.003